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Abstract
Background: 5,11,14 20:3 is similar to 20:4n-6 but lacks the internal ∆8 double bond essential for
prostaglandin and eicosanoid synthesis. When previously fed to laboratory animals as a
gymnosperm seed oil component it has shown anti-inflammatory properties.
Results: Herein, topically applied Podocarpus nagi methyl esters (containing 26% 5,11,14 20:3) were
incorporated into mouse ear phospholipids, reduced 20:4n-6, and reduced 20:4n-6- and TPA-
induced mouse ear edema. Purified 5,11,14 20:3 was taken up by cultured human skin
keratinocytes, reduced 20:4n-6, and reduced PGE2 levels dramatically. Purified 5,11,14 20:3 did not
affect PPARα, PPARγ, or PPARδ transactivation.
Conclusions: Topical application of 5,11,14 20:3 to skin surfaces can thus reduce inflammatory
processes, most likely by displacing 20:4n-6 from phospholipid pools and reducing downstream
inflammatory products derived from 20:4n-6 such as PGE2 and leukotrienes. It could have potential
use in treating clinical skin disorders resulting from overproduction of 20:4n-6-derived eicosanoid
products.
Background
Steroidal and non-steroidal anti-inflammatory drugs are
known to induce various cutaneous side-effects following
systemic and topical application to treat inflammatory
skin diseases such as chronic eczema, psoriasis, and sys-
temic lupus erythematosus [1–4]. Such side effects may be
overcome by replacement or co-utilization with orally or
topically applied anti-inflammatory lipids, such as fish
oil, containing 20:5n-3 and 22:6n-3 [5–7].
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A very rarely studied fatty acid (FA) with anti-inflammato-
ry potential is the non-methylene interrupted fatty acid
(NMIFA) 5,11,14 20:3 having structural similarity to
20:4n-6, but as a result of lacking the internal ∆8 double
bond, is not a substrate for prostaglandin and leukotriene
production, although small amounts of aborted side
products may be formed [8]. Very little 5,11,14 20:3 is
elongated [9] or converted to 20:4n-6 in mammals due to
limited (if any) ∆8 desaturase activity [10].
Most commonly consumed vegetable oils are derived
from angiosperms. In contrast, 5,11,14 20:3 is found in
various gymnosperm (conifer) species [11–14] and can be
synthesized in gymnosperms and animals by elongation
followed by "front-end" ∆5-desaturation (i.e., 9,12 18:2
→ 11,14 20:2 → 5,11,14 20:3). Like fish oil-derived
20:5n-3, 5,11,14 20:3 is also incorporated into PC and PE
pools resulting in reduced levels of 20:4n-6. However,
5,11,14 20:3 has more selectivity for the phosphatidyli-
nositol (PI) and phosphatidylinositolbisphosphate
(PIP2) pools when fed to mice [15,16], and when incubat-
ed with HepG2 cells [17,18]. This could affect diacylglyc-
erol-protein kinase C signaling [19,20]; as well as
monoacylglycerol signaling, particularly via interactions
with cannabinoid receptors [21]. 5,11,14 20:3 also has
poorer affinity for phospholipase A2, leading to potential
accumulation in phospholipid (PL) pools at low doses
[22]. Further, as compared to fish oil, NMIFA preparations
have a "non-fishy" odor, and reduced oxidizability with
only 2 methylene interrupted double bonds [23]. Previ-
ous studies showing anti-inflammatory potential of
5,11,14 20:3 are reviewed below.
In autoimmune mice, feeding of 5,11,14 20:3 suppressed
production of pathologic anti-erythrocyte- and anti-dou-
ble stranded DNA antibodies, and prolonged survival
[24,25]. In mice injected with collagen-adjuvant emul-
sions, mortality was lowest in mice fed Juniper oil with
11% 5,11,14 20:3 as compared to fish oil and controls
[26]. In mice fed Juniper oil and injected with lipopoly-
saccharide, PGE2, TXB2, 6-ketoPGF1α, IL-6, and IL-10
were decreased compared to controls, and Juniper oil was
as effective as fish oil in decreasing these pro-inflammato-
ry markers [27]. Oils containing 5,11,14 20:3 can also
lower plasma cholesterol in experimental animals [28].
Herein, we explored the topical anti-inflammatory poten-
tial of 5,11,14 20:3. We set out to answer the following
questions:
A) Is 5,11,14 20:3 incorporated into mouse ear PL when
applied topically, can it displace 20:4n-6 from PL pools,
and does 5,11,14 20:3 have potential to reduce ear ede-
ma?
B) Is 5,11,14 20:3 taken up by cultured human keratinoc-
yte PL, can it displace 20:4n-6 from PL pools and reduce
PGE2 levels, and does it affect tumor necrosis factor α(TN-
Fα) production?
C) Does 5,11,14 20:3 affect activation of peroxisome pro-
liferated activated receptor (PPARs), suggested to be mod-
ulators of the inflammatory response?
Results and discussion
Incorporation of topical 5,11,14 20:3 into mouse ear com-
bined phospholipids
In total mouse ear PL, 5,11,14 20:3 increased from 0.2–
13.6 %, and 20:4n-6 decreased from 9.9–2.2 % and
22:6n-3 from 9.3–1.0 % (Table 1). It is likely 5,11,14 20:3
replaced these PUFA on the sn-2 position of PL. The in-
crease in 18:2n-6 from 16.8–27.0 following P. nagi ad-
ministration may indicate some 20:2n-6 in P. nagi was
retroconverted to 18:2n-6 [29]. The replacement of 20:4n-
6 with 5,11,14 20:3 is consistent with P. nagi oil having
anti-inflammatory properties when applied topically to
skin.
Incorporation of topical 5,11,14 20:3 into mouse ear indi-
vidual phospholipids
Although the amount of ear tissue available was marginal
for individual PL determination, chromatographic analy-
sis indicated there was incorporation of 5,11,14 20:3 into
all individual PL classes examined: sphingomyelin, PC,
phosphatidylserine, PI, and PE. Interestingly, the greatest
incorporation was in the PI pool (data not shown). Previ-
ously, feeding experiments revealed greater incorporation
of 5,11,14 20:3 into mouse liver, spleen, kidney and heart
PI and PIP2, relative to other PL pools [15,16].
Incorporation of topical 5,11,14 20:3 into mouse ear neu-
tral lipids
As in previous mouse feeding experiments [16], there was
less incorporation of 5,11,14 20:3 into NL than PL pools
(2.2 vs.13.6%). In both NL and PL pools, there was a
small increase in 5,11 20:2, a minor P. nagi component
(Table 1).
Effects on edema
Topical P. nagi ME (rich in 5,11,14 20:3) inhibited 20:4n-
6-induced edema 57% (measured 6 h after 20:4n-6 addi-
tion; Figure 1). Control ME did not reduce edema and did
not produce irritant effects (data not shown).
Arachidonic acid induced edema could have been reduced
via the following mechanisms: 1) the incorporation of
5,11,14 20:3 into mouse ear PL reduced endogenous lev-
els of 20:4n-6 available for release and conversion to ede-
ma-inducing eicosanoids, such as PGE2; and leukotrienes;
and 2) less exogenously added 20:4n-6 could be convert-Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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ed to edema-inducing eicosanoids. There is not evidence
from previous experiments that 5,11,14 20:3 can inhibit
conversion of free 20:4n-6 to eicosanoids, whether re-
leased from membranes or added exogenously. Exoge-
nously added 20:4n-6 may need to first be incorporated
into PL before release and conversion to eicosanoids. It
could be topically added 5,11,14 20:3 impaired the incor-
poration of exogenously added 20:4n-6 into PL. The fact
that indomethacin reduced 20:4n-6-induced edema, is
also consistent with 20:4n-6 conversion to pro-inflamma-
tory cyclooxygenase products.
In another set of experiments, relative to TPA alone, after
daily application of 20 wt% P. nagi intact oil for 5 d, ear
edema was significantly (p < 0.05) reduced from 6.2 ± 1.0
to 3.4 ± 0.7 (1/100 mm; mean of 5 replicates ± 1 SD), 1 h
after addition of 0.01% TPA (45% reduction); and from
31.0 ± 1.8 to 22.0 ± 1.8, 24 h after addition of TPA (29%
reduction). There was also a reduction in edema with a 5
wt% concentration of P. nagi intact oil, with edema re-
duced from 6.2 ± 1.0 to 1.8 ± 1.3, 1 h after addition of TPA
(71% reduction; p < 0.05); and from 31.0 ± 1.8 to 28.6 ±
1.6, 24 h after addition of TPA (8% reduction, not signif-
icant). In the above experiment, dexamethasone (0.1%)
was used as a positive control.
Relative to the same concentration of control ME mix, 20
wt% P. nagi ME reduced ear edema from 17.0 ± 3.3 to 3.4
± 0.7, 1 h after TPA addition (80% reduction), but did not
reduce ear edema 24 h after TPA addition. In this experi-
ment, an irritant effect was however apparent after 1 h,
since edema values for TPA alone were only 6.2 ± 1.0.
Thus a lower concentration of ME was also evaluated. Rel-
ative to 10 wt% concentration control ME, P. nagi ME sig-
nificantly reduced edema from 6.4 ± 0.7 to 3.4 ± 1.4, 1 h
after TPA addition (47% reduction); no reductions were
seen 24 h after TPA addition.
Some of TPA's biological actions are to enhance the re-
lease of 20:4n-6 from PL via kinase activation of phos-
pholipase A2 and to inhibit 20:4n-6 conversion to PGE2
by inhibiting cyclooxygenase-2 [30,31]. It is likely that fol-
lowing the 5 d application of P. nagi lipids, less 20:4n-6
substrate was available for TPA-induced 20:4n-6 release
from PL [32].
Other investigators have similarly shown TPA-induced
mouse ear edema to be reduced by feeding purified 20:5n-
3 and 22:6n-3, FA known to reduce 20:4n-6 in PL [6]. Ad-
ditionally, in a recent study, various topically applied
plant extracts used in traditional East Asian medicine
against different skin disorders, were found to inhibit
Table 1: Fatty acids in lipid pools following application of control and P. nagi ME to mouse ears
FA Percentage Phospholipid Neutral lipid
Control P. nagi Control P. nagi
16:0 14.6 8.2 13.8 13.5
16:1n-7 1.6 5.9 28.8 33.6
18:0 14.8 7.6 1.8 1.5
18:1n-9 20.0 15.5 31.8 28.8
18:2n-6 16.8 27.0 12.1 8.9
18:3n-3 0.0 0.3 0.4 0.3
20:2 5,11 0.0 0.2 0.0 0.4
20:3 5,11,14 0.2 13.6 0.1 2.2
20:2n-6 0.8 4.4 0.3 1.2
20:3n-6 0.7 0.2 0.1 0.1
20:4n-6 9.9 2.2 0.7 0.5
20:5n-3 0.3 0.0 0.2 0.3
23:0 0.3 0.0 0.1 0.0
22:2n-6 0.2 0.0 0.1 0.0
22:4n-6 1.1 0.0 0.1 0.0
22:5n-3 1.0 0.0 0.1 0.0
22:6n-3 9.3 1.0 0.6 0.5
Σ 12:0, 13:0, 14:0, 15:0 1.9 2.5 4.1 4.5
Σ 20:0, 22:0, 24:0, 26:0 4.4 9.7 2.2 0.8
Σ 20:1n-9, 22:1n-9, 24:1n-9 2.1 1.7 2.8 3.0
Lipids were extracted from 4 combined ear biopsies (20 mg tissue), PL and NL separated on silica columns, methylated, and analyzed by gas chro-
matography. Values represent the mean of 1 pooled replicate (duplicate gas chromatographic analysis). Control ME mixture consists of safflower/
sunflower/apricot (43:2:50, by vol); P. nagi refers to the ME mixture derived from a gymnosperm seed oil described in the text.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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Figure 1
Reduction in mouse ear edema following addition of P. nagi ME P. nagi ME or oil (20 wt% in acetone) was applied top-
ically once daily for 5 d, and edema measured 6 h after 20:4n-6 addition. Indomethacin was used as a positive control. A con-
trol methyl ester mix did not reduce edema (not shown in figure). Values represent mean of 5 replicates. Error bars represent
1 SD. AA, arachidonic acid.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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TPA- and 20:4n-6-induced edema [33]. The content of
5,11,14 20:3 in the tested plants was not reported.
Although eicosanoids can also be generated from 20:4n-6
released from monoacylglycerols or diacylglycerols [34],
it is not likely 5,11,14 20:3 influenced this process since
little 5,11,14 20:3 was incorporated into NL pools (Table
1). There is also the speculative possibility topically ap-
plied 5,11,14 20:3 was converted to an N-5,11,14-eicosa-
trienoylethanolamine derivative [35] with anti-
inflammatory properties [36].
In the above experiments, it is not clear why the intact P.
nagi oil was effective in the TPA induced edema assay, but
not the 20:4n-6 induced edema assay. Nor is it clear why
intact P. nagi oil was effective 1 and 24 h after TPA addi-
tion, whereas P. nagi ME was only effective 1 h after TPA
addition. This difference could be related to enhanced sta-
bility of the triacylglycerol form compared to the ME
form. Nevertheless, there were important first indications
that the active component, 5,11,14 20:3 had the potential
to reduce edema following a 20:4n-6 or TPA challenge.
Incorporation of 5,11,14 20:3 into cultured keratinocytes
Cellular incubation conditions were carefully developed
to possibly mimic the cellular metabolism of dietary
5,11,14 20:3, and test the anti-inflammatory potential of
5,11, 14 20:3 in vitro. 5,11,14 was incubated for a long pe-
riod of time to allow it to be taken up by cellular PL and
accumulate in PL (as a result of a supposed poor affinity
for phospholipase A2); and to eventually, displace 20:4n-
6 from PL pools resulting in less production of 20:4n-6
derived anti-inflammatory products, following challenge.
Under the incubation conditions employed, 15 µM puri-
fied 5,11,14 20:3 ME was found to be incorporated into
cultured human skin keratinocyte PL at 3.3% and to de-
crease 20:4n-6, whether 5,11,14 20:3 was added alone
(Experiment 3 vs 2; Table 2), or with exogenous 20:4n-6
present in the system (Experiment 5 vs 4).
Effect of 5,11,14 20:3 on PGE2 and TNFα secretion in TPA-
treated keratinocytes
Thus far, we have shown that 5,11,14 20:3 can be incor-
porated into cultured keratinocytes and mouse ear PL, and
in both cases, reduce 20:4n-6 pools. The mouse ear exper-
iments indicated that the reduction in 20:4n-6 might re-
duce edema, following a 20:4n-6 or TPA challenge. In the
next set of in vitro experiments, we determined whether
5,11,14 20:3 might directly reduce the pro-inflammatory
eicosanoid, PGE2, and the pro-inflammatory cytokine
TNFα, since both these products are known to be at least
partly modulated by cellular 20:4n-6 levels.
Relative to 6 d incubation with 20:4n-6 alone, PGE2 was
decreased with 100–200 µM 5,11,14 20:3 added during
the last 4 d of incubation in combination with 20:4n-6
(Figure 2), but TNFα was slightly increased (Figure 3).
PGE2 was in fact reduced to the same levels as seen with
hydrocortisone (data not shown). Although the incuba-
tion conditions were not identical to those employed for
the experiments in Table 2, it is likely that a 5,11,14 20:3-
mediated reduction in 20:4n-6 is responsible for the ob-
served decrease in PGE2. The concentration of 100–200
µM 5,11,14 20:3 may be on the high side as far as fatty
acid cell culture doses are concerned, but there were no in-
dications based on microscopic evalution of the cells, and
lack of killing of the cells, that this was a cytotoxic concen-
tration, producing detergent like effects.
The increase in TNFα may be the result of either TNFα
synthesis or secretion. Mechanistically, the increase may
be related to the observed decrease in PGE2, since high
levels of PGE2 can inhibit TNFα production and transcrip-
tion [37–39]. Although TNFα is a pro-inflammatory
marker, we have evidence 5,11,14 20:3 reduced skin in-
flammation in the ear edema assay and decreased PGE2 in
keratinocytes. The kinetics of formation of TNFα and a
range of eicosanoids needs to be studied to more fully un-
derstand anti-inflammatory actions of 5,11,14 20:3.
Effects of 5,11,14 20:3 on PPAR transactivation
PPARs are an extremely important class of nuclear recep-
tors with a plethora of diverse roles. Recently, PPARs were
suggested to modulate the inflammatory response
[40,41]. PPARs can be activated by polyunsaturated FA
[42] including FA with non-methylene interrupted double
bond arrangements such as conjugated linoleic acid [43].
Thus, it was important to evaluate whether 5,11,14 20:3
and other FA could activate PPARs (Table 3). As previous-
ly reported, PPARα was induced with 22:6n-3 [44] and
9,11/10,12 18:2 (conjugated linoleic acid) [43]. The in-
duction PPARγ and δ with 22:6n-3 may be a new finding.
Importantly, 5,11,14 20:3 did not affect transactivation of
human PPARα, δ and γ expressed in HeLa cells. It is thus
unlikely activation or inhibition of PPARs is important for
biological activity of 5,11,14 20:3. These experiments
should be repeated in keratinocytes transfected with dif-
ferent PPAR sub-types.
Conclusions and Key findings
Previous studies showed that the 20:4n-6 analog, 5,11,14
20:3, is biologically active when fed to mice [15,16]. Here-
in, we showed that 5,11,14 20:3 is biologically active
when applied topically in cell culture and in vivo. In cul-
tured keratinocytes, 5,11,14 20:3 was incorporated into
PL, reduced levels of 20:4n-6, reduced levels of the 20:4n-
6-derived pro-inflammatory product, PGE2, and tempo-
rally increased TNFα production. In the mouse ear-edemaLipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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Figure 2
Reduction in PGE2 secretion of human keratinocytes following incubation with 5,11,14 20:3 ME DK2-NR kerati-
nocytes were incubated for 6 d with 15 µM 20:4n-6 (control) or with 2 d 15 µM 20:4n-6 plus 4 d of 15–200 µM 5,11,14 20:3.
In all experiments, 10 ng/mLTPA was also added. Values represent mean of 3 replicates. Error bars represent 1 SD.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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Figure 3
Increase in TNFα secretion of human keratinocytes following incubation with 5,11,14 20:3 ME. Refer to Figure 2
for experimental details. Values represent mean of 3 replicates. Error bars represent 1 SD.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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assay, 5,11,14 20:3, as a component of P. nagi ME and oil,
was similarly incorporated into PL (and the PI pool), re-
duced levels of 20:4n-6, and decreased 20:4n-6- and TPA-
induced edema production. PPARs are most likely not in-
volved in the cutaneous biological activity of 5,11,14
20:3.
NMIFA preparations have the potential to reduce inflam-
mation when applied directly to superficial tissues, and
could also active when injected underneath superficial tis-
sues. Topical application of NMIFA could be extended to
inflammations of the buccal, optic, nasal, colonic, anal,
and vaginal surfaces [45].
For 5,11,14 20:3 to be developed for such dermatologic
and medical uses, it must not only be effective, but readily
available and safe. 5,11,14 20:3 can be synthesized chem-
ically [46,47], or purified from a gymnosperm seed oil as
described herein. In addition to the P. nagi starting source,
it is found at levels of 6–90 wt% in various other gymno-
sperms [14]. The fungal species Mortierella alpina is a cur-
rent commercial source of 20:4n-6 with Generally
Regarded as Safe (GRAS) status in the United States for in-
fant formula applications (FDA GRAS Notice No. GRN
000041, May 17, 2001). By chemically inhibiting the ∆6
desaturase in this species, or by developing mutants with
a poor ∆6 desaturase [48], and incubating the culture me-
dium with the precursor 20:2n-6 [49], large amounts of
5,11,14 20:3 can be potentially produced.
With respect to safety, there is some evidence 5,11,14 20:3
is already consumed in the diet. In Japan, T. nucifera (11%
5,11,14 20:3) is consumed in the form of salad oil, crack-
ers and bean paste [13]. In China and in Chinese herbal
markets in the United States (and perhaps elsewhere),
Platycladus orientalis seeds (3% 5,11,14 20:3) are con-
sumed [12]. Of particular interest, the large tasty seeds of
Araucaria araucana (Monkey puzzle, Chilean Pine; 90%
5,11,14 20:3) are still consumed by indigenous peoples in
Argentina and Chile [14].
Table 2: Incorporation of 5,11,14 20:3 into cultured keratinocyte phospholipids
Treatment with fatty acids Fatty acids incorporated into total phospholipids (%)
Exp # Day 0 Day 2 Day 4 5,11,14 20:3 20:3n-6 20:4n-6 20:5n-3
1 - EtOH EtOH 0.00 0.11 0.43 0.04
2 - 5,11,14 20:3 5,11,14 20:3 3.34 0.17 0.47 0.06
3 20:4n-6 20:4n-6 0.30 0.55 10.39 0.00
4 20:4n-6 5,11,14 20:3 5,11,14 20:3 2.12 0.38 5.30 0.03
5 20:4n-6 20:4n-6 20:4n-6 0.09 0.85 11.80 0.03
Human DK2-NR keratinocytes were incubated in NR-2 medium containing 15 µM concentrations of various FA methyl esters for up to 6 d as indi-
cated above. Exp, Experiment. Values represent mean of 3 replicates.
Table 3: Induction of transactivation of PPARs
PPARα PPARγ PPARδ
FA 100 µM2 0 0   µM1 0 0   µM2 0 0   µM1 0 0   µM2 0 0   µM
18:2n-6 23 43 8 12 11 13
2 0 : 3 n - 6 1 71 93 3 2 04
2 0 : 3 n - 3 1 94 91 83 05 36 7
5,11,14 20:3 16 35 22 27 28 56
9,11/10,12 18:2 76 98 11 14 15 32
22:6n-3 65 574 50 298 140 428
Luciferase activity in HeLa cells transfected with human PPARα, δ and γ cDNAs measured 24 h after addition of unesterified FA at indicated concen-
tration. Values represent % of transactivation values obtained in presence of the positive control Wy14,643 at 10 µM for PPARα, and of BRL49653 
at 1 µM for PPARγ and PPARδ, taken as 100%. Significant activation is considered >50% of Wy14,643 for PPARα; >75% of BRL49653 for PPARγ and 
>100% of BRL49653 for PPARδ. Under the assay conditions employed, inhibition values could not be determined. Values represent mean of 3 rep-
licates in independent experiments, with 4 replicates in each experiment.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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In summary, 5,11,14 20:3 remains a promising natural
compound for reducing inflammation induced by over-
production of 20:4n-6 and might be valuable clinically for
treating various skin diseases. The anti-inflammatory
properties of 5,11,14 20:3 should be further evaluated in
combination with nutritional components having differ-
ent mechanisms of action. These include: 1) the fish oil
component 20:5n-3 which reduces 20:4n-6 more from PC
and PE than PI pools, and leads to 15-lipoxygenase con-
version to the anti-inflammatory 15-hydroxyeicosapen-
taenoic acid product; 2) the fish oil component 22:6n-3
which has anti-inflammatory properties following 15-
lipoxygenase conversion to 17-hydroxydocosahexaenoic
acid; 3) the borage and evening primrose oil components
18:3n-6 and 20:3n-6 [50], which have anti-inflammatory
properties following cyclooxygenase conversion of 20:3n-
6 to PGE1, and 15-lipoxygenase conversion of 20:3n-6 to
15-hydroxyeicosatrienoic acid; and 4) with 18:2n-6 which
has antiproliferative properties following 15-lipoxygenase
conversion to 13-hydroxy-9,11-octadecadienoic acid [7].
5,11,14 20:3 may also reduce inflammation synergistical-
ly when combined with non-steroidal anti-inflammatory
drugs that inhibit cyclooxygenase-2, particularly at lower
doses, where the conversion to prostaglandins, but not
the release of 20:4n-6 from PL pools via phospholipase
A2, is inhibited [51].
Materials and methods
Seeds
Podocarpus nagi (Podocarpaceae) seeds were obtained
from Carter Seeds (Vista, CA) and contained 14% fat (dry
wt. basis), 26% 5,11,14 20:3, and trace amounts of other
trienes [11].
Lipid extraction, degumming, bleaching, and methylation
Seeds (1 Kg) were extracted with isopropanol and CHCl3
mixtures, evaporated under N2 (further operations were
performed under N2 where possible), dissolved in hexane,
and washed with 1% NaCl [52]. Crude oil (90 g) was de-
gummed at 70°C for 1 min, mixed with 270 µL 85% or-
tho-phosphorate, heated 10 min with 1.8 mL HOH, and
centrifuged at 2000 g 5 min. For bleaching, 2.4 g of active
coal (Carbopal Gn-A, Chemische Fabrik, Brugg, Switzer-
land) and 80 g degummed oil were heated at 80°C for 20
min under vacuum, and filtered through a 50°C Buchner
funnel to obtain 76 g oil [53]. For methylation, 20 g deg-
ummed/decolored oil in 50 mL CHCl3 was mixed with
100 mL 2% methanolic H2SO4, heated 22 h at 65°C, neu-
tralized with 200 mL 5% NaCl, redissolved in 80 mL hex-
ane, and washed with 80 mL 2% Na bicarbonate [54]. FA
composition of P. nagi methyl ester (ME) mix (before col-
umn purification) was: 2.4% 16:0; 1.4% 18:0; 16.4%
18:1n-9; 43.1% 18:2n-6; 0.4% 5,11 20:2; 26.3% 5,11,14
20:3; 8.6% 20:2n-6; and 1.4% 20:0/22:0/24:1n-9 com-
bined. FA ME were analyzed on an HP 6890 gas chroma-
tograph with SGE BPX-70 capillary column and identified
by retention time and gas chromatography/mass spectros-
copy [48].
Florisil column chromatography to purify 5,11,14 20:3
Argentation chromatograpy, which separates compounds
based on number of double bonds, was used to obtain
5,11,14 20:3 free of other trienes. Florisil (600 g, 60–100
mesh; Fluka Chemie AG, Buchs, Switzerland) was double
acid-washed with H2SO4, MeOH and CHCl3 [55], mixed
with 5% aq AgNO3 (25% apparent impregnation), dried,
and activated at 110°C [56]. A 300 g slurry of sorbent, 500
mL hexane and 20 g P. nagi ME were added to a 100 × 4
cm column with 10°C water-cooling jacket. Flow rate was
adjusted to 4 L/d. Various 2 L vol ratios of hexane/diethyl
ether from 100:0–0:100 (v/v) were added, and 33 1 L frac-
tions collected over 10 d [57,58]. From 20.0 g P. nagi ME
(containing 5.3 g 5,11,14 20:3) applied to the column,
4.0 g 5,11,14 20:3 were recovered in combined fractions;
4 fractions contained 1.3 g 5,11,14 20:3 in 100 % measur-
able purity. For cell culture experiments, 10 mg 5,11,14
20:3 ME was processed to reduce any contaminating silver
ions [59]; for PPAR experiments, ME were converted to
unesterified FA [54].
Preparation of control ME mix for ear edema experiments
A ME control oil mixture prepared from safflower/sun-
flower/apricot (43:2:50, by vol.) contained: 5.4% 16:0;
0.3% 16:1n-7; 1.9% 18:0; 43.9% 18:1n-9; 48.5% 18:2n-6
and 0.1% 20:5n-3. In control oil, 18:1n-9 (43.9%) con-
tent approximately equaled 18:1n-9 (16.4%) + 5,11,14
20:3 (26.3%) content in P. nagi oil; 18:2n-6 (48.5%) con-
tent approximately equaled 18:2n-6 (43.1%) + 20:2n-6
(8.6%) content in P. nagi oil. Thus, the less common FA
(20:2n-6) and FA with anti-inflammatory potential
(5,11,14 20:3) in P. nagi oil were replaced by 18:2n-6 and
18:1n-9 in control oil.
Lipid extraction and analysis of ear phospholipids
Following topical application of P. nagi or control ME, 4
ear biopsies per treatment were pooled to yield 20 mg ear
tissue, which was ground with a teflon pestle, extracted
with 0.8 mL HOH, 1 mL CHCl3 and 2 mL MeOH, vor-
texed, centrifuged (3 min, 1000 g), and the residue re-ex-
tracted with 1 mL CHCl3. Pooled supernatants were
filtered through sintered glass, washed with 1 mL 0.88%
KCl, vortexed, centrifuged, and the organic phase redis-
solved in 2 mL CHCl3 and applied to pre-washed 3 mL
500 mg silica solid phase extraction columns (Supelco
Inc., Buchs, Switzerland). Neutral lipid (NL) were ob-
tained with 4 mL CHCl3; and PL with 4 mL CHCl3/MeOH
(2:1, by vol) and 4 mL MeOH [60]. Total PL were checked
for purity by high performance thin layer chromatography
(HPTLC); or separated into individual classes by HPTLC,Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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scraped, methylated, and FA composition determined by
gas chromatography [Table 1; [61]].
Ear edema assay
Right mouse ears were topically treated 1 X/d for 5 d with
20 wt% P. nagi ME or intact oil (4 µg in 20 µL acetone)
containing 0.5 wt% α-tocopherol and 0.2 wt% palmitoy-
lascorbate as antioxidants [62]. Left ears received 20 µL ac-
etone. Unesterified 20:4n-6 (20 wt%) in acetone was then
applied topically 1 h after the last administration of P.
nagi ME, and left on the ears for 6 h, during which time ear
edema was measured with calipers (Figure 1). Ear biopsies
were taken for PL analysis 2 h after 20:4n-6 addition in
some studies (Table 1). Ear edema experiments were ap-
proved by an internal animal care and use committee.
Growing conditions for keratinocytes and incorporation of 
5,11,14 20:3 into PL
The newly developed SV40 T-Ag immortalized human ke-
ratinocyte line DK2-NR, having a highly conserved meta-
bolic profile, was used to study 5,11,14 20:3 metabolism
[63]. Cells were cultured in NR-2 serum-free medium (Bi-
osource Inc., Rockville, MD) developed for immortalized
keratinocytes [63]. This is an essential FA-deficient culture
medium with low Ca2+ concentration (0.11 mM Ca2+)
containing bovine pituitary extract, EGF, insulin, hydro-
cortisone and transferrin. To improve cell adhesion, cul-
ture dishes were preincubated with a coating solution
consisting of 1 L basal medium (without growth factors)
supplemented with 10 mg/L human fibronectin (Becton
Dickinson), 100 mg/L BSA (Biosource Inc., Rockville,
MD), and 160 mg collagen/L (Vitrogen 100, Corporation,
Palo Alto, CA). Cells were cultured in NR-2 medium until
confluency, then shifted to high Ca2+ (1.5 mM Ca2+). Af-
ter 4 d, purified 5,11,14 20:3 ME was suspended in NR-2
medium and added to DK2-NR cell cultures (experiments
1–2, Table 2). Controls were incubated with 15 µM 20:4n-
6 ME under identical conditions (experiment 3, Table 2).
Medium containing fresh FA was added every 2 d in exper-
iments exceeding 2 d incubation. Cells were also pre-incu-
bated 2 d with 15 µM 20:4n-6 ME for 2 d and
subsequently with 15 µM 5,11,14 20:3 ME, or with only
15 µM 20:4n-6 ME added every 2 d (experiments 4 and 5,
Table 2). 5,11,14 20:3 ME and 20:4n-6 were warmed and
sonicated in 1 mg/mL FA-free bovine serum albumin
(BSA, Sigma) prior to addition. Following incubations,
cells were washed in Hank's Balanced Salt solution (HB-
SS) containing 0.1% BSA, harvested, centrifuged in 1 mL
HBSS (1000 rpm), and lipids extracted, PL separated by
HPTLC, methylated, and FA ME quantified by gas chro-
matography (Table 2).
As compared to primary keratinocytes, we used the above
cell line because it is more standardized, previously adapt-
ed to essential fatty acid deficient growing conditions, and
because its FA metabolism has been previously evaluated
under these conditions [63]. Cells were shifted to high cal-
cium to induce differentiation, to better mimmic the in
vivo situation, and because cells differentiated in this man-
ner were known to be less sensitive to high doses of die-
tary FA, including 18:2n-6 and 18:3n-3 [63]. For DK2-NR
cell experiments, we used ME, rather than unesterified FA,
because ME are more stable to oxidation when using se-
rum-free media with limited antioxidants; and because
our cell line was previously established to posess suffi-
cient methyl esterase activity to convert the ME to unester-
ified fatty acids.
Measurement of PGE2 and TNFα in keratinocytes
Confluent DK2-NR cell cultures were incubated in NR-2
medium containing 1.5 mM CaCl2. Cells were incubated
for 2 d with 15 µM 20:4n-6 then for 4 d with either: 15 µM
20:4n-6; or 15 µM 20:4n-6 + 15-, 50-, 100-, or 200 µM
5,11,14 20:3 ME (Figs. 2,3; similar to Experiment 4 of Ta-
ble 2 except there was co-incubation of 20:4n-6 with
5,11,14 20:3 during the final 4 d of the 6 d incubation pe-
riod). In other experiments, the total time of incubation
with FA was up to 10 d (data not shown). Fresh FA were
added every 2 d; and 10 ng/mL of the PGE2-inducer TPA
was added on incubation d 5. On d 6, supernatant was
collected for ELISA-quantification of TNFα (R&D systems
Minneapolis, USA) and PGE2 (Cayman Chemical Com-
pany, Ann Arbor, MI, USA).
PPAR Transactivation assay
Three copies of acyl-CoA oxidase PPRE (5' GATC-
CCCGAACGTGACCTTTGTCCTGGTCC-3') were cloned
into the BglII site of pGL3 vector (Promega, France) con-
taining SV40 promoter and luciferase gene. Human PPA-
Rα,  δ and γ cDNAs were cloned in the mammalian
expression vector pSG5. HeLa cells were seeded in a 150
mm diameter Petri dish in Dulbecco's Modified Eagle Me-
dium (DMEM) containing 10% (v/v) delipidized fetal calf
serum. After 24 h, cells were co-transfected with the PPAR
expression and reporter plasmids using CaPO4 precipita-
tion [64]. After 18 h, cells were trypsinized, seeded into 96
well clusters, and unesterified FA added to culture medi-
um (Table 3). Positive controls for PPARα and PPARδ/γ
activation were 10 µM Wy-14,643 and 1 µM BRL49653,
respectively. Luciferase activity was determined after 24 h
with a Luclite kit (Packard Instrument, France) on a Mi-
crobeta Trilux Wallac luminescence counter (EG & G
Berthold, France; Table 3). Unesterified FA, as opposed to
ME, were tested because the HeLa cell PPAR expression re-
porter assay had been validated with unesterified FA; and
because there would be little oxidation risk during the 1 h
short incubation period (unesterified FA being less stable
than ME). The higher doses of 100–200 µM were not cy-
totoxic to cells under our culture conditions as assessed by
trypan blue exclusion and the fact that a wide range of FALipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/5
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with known activation properties behaved as reported in
literature (e.g., 22:6n-3, Table 3).
Abbreviations
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FA fatty acid
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TNF tumor necrosis factor
TPA 12-O-tetradecanoylphorbol-13-acetate
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